Position in SCLX
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$23
+$4 QoQ
Shares Held
3
-40.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#60
of 72 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SCLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Parallel Advisors, LLC holds $119,634,223 across 18 Drug Manufacturers - General names. SCLX ranks #18 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
31,933 | $38,301,401 | |
| 2 | ABBV |
AbbVie Inc.
|
100,846 | $25,376,887 | |
| 3 | JNJ |
Johnson & Johnson
|
83,035 | $21,088,398 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
76,862 | $9,710,745 | |
| 5 | MRK |
Merck & Co., Inc.
|
66,774 | $8,580,459 | |
| 6 | AMGN |
Amgen Inc
|
11,139 | $4,033,654 | |
| 7 | NVO |
Novo Nordisk A S
|
56,877 | $2,726,683 | |
| 8 | NVS |
Novartis AG
|
15,640 | $2,451,100 |
All Filings in SCLX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23 | 3 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $19 | 3 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $36 | 3 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $255 | 13 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $17 | 3 | Shares | Sole | 2025-07-08 | |
| No filing history on record for this holder in this stock. | ||||||